/
Not financial advice. Analytical data for research only.
Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.
In the future, if and when any product candidates we may develop receive FDA approval, we expect to apply for patent term extensions on issued patents covering those product candidates. Moreover, we intend to seek patent term adjustments and extensions for any of our issued patents in any jurisdiction where such adjustments and extensions are available.
$17.11
$0.95 (-5.26%)
EOD Sep 18, 2026
Negative free cash flow of -$405M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue
N/A
Net Income (TTM)
-$519M
▼ -40.6% YoY
Op. Margin
—
ROIC
-43.41%
▲ +29.1pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$480M
▼ -37.4% YoY
Op. Cash Flow (TTM)
-$478M
▼ -37.9% YoY
Net Debt
-$679M
Net Cash Position
Cash & Equiv.
$898M
Continue Research
SourceComputed from the 10-Q filed 29 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 30 Jul 2026. How this is calculated.
Price from market data, last close as of 18 Sept 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.